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284 pp. $27.95Presuming you’re a biomedical re-
searcher of some sort, try these ques-
tions. Have you ever had difficulty
explaining what your work is like to
someone completely outside of the field?
Have you ever wished for a short book
that would explain to your nonscientific
friends and relatives just what it is that
you do with all of your time? And why it
so often seems very complicated? If so,
The Quest for the Cure by Brent R. Stock-
well might do the trick.
The book is, among other things, a short
history of drug discovery research during
the last 25 years or so. It covers the broad
changes and trends that have shaped the
field, such as the excitement about struc-
ture-based drug design and combinato-
rial chemistry and then the genomics
frenzy. (As a medicinal chemist, I see
many of these as varied attempts to
‘‘stop paying so much for chemistry,’’
but there are no doubt other ways to
look at it.) While doing so, the book also
traces some early pharmaceutical history,
going back to the 19th and early 20th
centuries. Although the constant switch-
ing between new topics and flashbacks
can be a bit wearying at times, Stockwell
tells the right stories to get his points
across.
These points are that: (1) the easier,
more tractable drug targets are in the
process of running out (if they haven’t
already) and (2) the future of drug dis-
covery lies in the hitherto ‘‘undruggable’’
targets such as transcription factors and
protein-protein interactions in general.
Not everyone in the field will agree with
all parts of his argument, but I think that
its general point is hard to deny. There is
no doubt that extending drug discovery
into these areas could be tremendously
useful, and there is also no doubt that
our present tools are not really up to the
task.
To my mind, though, there are at least
two rather pessimistic views that do not16 Cell 146, July 8, 2011 ª2011 Elsevier Inc.getmuch of an airing in what is fundamen-
tally an optimistic book. The first is the
fact that, even among the druggable
targets, all too many attempts to exploit
them fail. Some of these are due to
toxicity (the details of which are not
always well understood, to put it gently),
but a great many are outright failures of
efficacy due to our incomplete knowledgeof biochemistry. Reading this book, one
might almost get the impression that
most such details have already been
worked out and that all that is needed
are the tools to go in and tickle the right
proteins. But what do we do when we
don’t know what the right proteins are
or, worse, when we have the wrong ones
picked out? There is a vast amount of
spadework and brush clearing still to be
done. (One response to this objection is
that, if we had better tools to probe such
things as protein-protein networks, we
would be able to clear these questions
up more quickly.)The second, even bleaker view is that
some of these targets may, in fact, not
be druggable at all by any useful technol-
ogies. I am reluctant to put things in this
category, being somethingof a technolog-
ical optimist myself, but it is not some-
thing that can be ruled out. In every field,
there are things that we understand that
we still cannot manage, affect, or exploit,
no matter how subtle our tools. A long
treatment of that point would not, how-
ever, be a book that anyone would partic-
ularly want to write (or read). And this
cannot be the case for every new class
of target, one hopes.
If we assume then that there will be
next-generation tools, what will they
look like? Stockwell introduces readers
to a completely up-to-date range of
things that might do the job. Brief but
accurate tours are given for topics such
as fragment-based drug design, stabi-
lized peptides, and other engineered
biologics, combinatorial chemistry, diver-
sity-oriented synthesis, and more. A
long list of well-known names and com-
panies make appearances (with, it must
be noted, an especially high concentra-
tion in Cambridge, MA). Stockwell is
scrupulously fair about assigning credit
when reviewing the history of a given
area, and even working scientists in
drug discovery will probably learn some
new details about how some of these
developed.
His explanations seem quite good to
me, but I am not a very good test subject,
as I already know what Stockwell is trying
to convey. This is difficult material to
cover accurately at less than its original
level of detail, but I think that he does as
good a job as can be done. My only real
problem with his explanations is with the
illustrations that have been added to
them. There are not very many of them,
to start with—only four color plates that
are not particularly well used. And the
black and white line drawings vary hugely
in quality and utility, from a perfectly
decent schematic of a stapled peptide
all the way down to a less than useful
representation of the common drug
targets in a cell. A glance through the
figures would give a browsing reader no
idea of the quality of the text itself.
Each chapter is thoroughly footnoted
with references to both the original and
secondary literature. But that brings up
another question, one that always occurs
with books of this sort: who is the in-
tended audience? A general reader will
be unlikely to pursue a reference all the
way back to the Journal of the American
Chemical Society (but may feel some
comfort knowing that everything is
backed up so thoroughly by the real
scientific literature). I always wonder
how large the market is for general scien-
tific titles like this.And it wouldn’t be surprising if many
copies of this book get distributed in the
way that I suggested in the first para-
graph. This would be no bad thing. This
book deserves a readership, and there is
certainly a need for it. As a drug company
researcher, I have often wished that more
people understood what the field was like
and how simultaneously fascinating and
frustrating it can be. The number of
people who have no idea whatsoeverCabout where drugs come from and how
is staggering.
Stockwell’s own suggestions on how to
remedy this problem appear in a final
chapter that seems rather tacked on.
They seemed doomed to me—worthy
public awareness and education pro-
posals that might as well come under a
banner that says ‘‘Eat Your Peas, They’re
Good For You.’’ A better solution would
be for more people to read his book.Derek B. Lowe1,*
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